NASDAQ:INTS 30 October 2025 - 31 October 2025

Intensity Therapeutics has been one of the market’s biggest movers. On Oct. 30, 2025 its stock was around $0.27 per share investing.com – an 84% drop YTD but up nearly 200% intraday on the news of its Lancet-published trial tipranks.com. Trading volume exploded: ~279 million shares traded on Oct. 30 vs. an average of ~5 M per day tipranks.com. The rally was sparked by the Phase 1/2 study announcement that Intensity’s lead drug, INT230‑6, showed striking tumor control in advanced cancer. The study covered 64 patients across 20+ tumor types – most had failed multiple therapies. Remarkably, 75% of patients experienced disease stabilization or response, and median overall survival was 11.9 months investing.com, far above historical norms. Company President/CEO Lewis Bender hailed the data and noted that Intensity has already launched further trials: “Given the drug’s mechanism of action and the data reported in this paper… we believe the study results show the potential of INT230‑6 to achieve clinical benefit for metastatic patients of multiple cancer types… As a result, we have initiated randomized controlled studies, including a Phase 3 study in sarcoma.” tipranks.com.